PCN261 CAR-T THERAPIES: REIMBURSEMENTS ABOUND, BUT WITH STRINGS ATTACHED.

The first two CAR-T cell therapies, Kymriah® (tisagenlecleucel) and Yescarta® (axicabtagene ciloleucel) received European marketing authorizations in August 2018 (Kymriah® for ALL and DLBCL and Yescarta® for DLBCL/PMBCL). Results Twenty five HTA evaluations of CAR-T cell therapies in scope countries were identified (8 Kymriah® ALL, 8 Kymriah® DLBCL, 7 Yescarta® DLBCL/PMBCL, 1 Yescarta® DLBCL, and 1 Yescarta® PMBCL) completed at an average of 7.5 months after European marketing authorization. The NLT accepted Kymriah® (ALL) and Yescarta® (DLBCL/PMBCL) following a delay, but rejected Kymriah (DLBCL). [Extracted from the article]